Happy New Year to all the shareholders and officials who are sending us support!

I believe that 2022 will be the year in which your hopes come true, with sales results based on real world reference and SCI thesis in 2021 in a difficult situation due to Corona for two years.

As a result of using Anyfusion, which you trusted, invested, and supported, in clinical practice, it is expected to be a must-have equipment in ICU and NICU in the future as a real-time accurate drug injection pump that is medical and clinically desired.

No matter how good the technology is, the process of changing the paradigm is difficult and difficult. We are making steady efforts for patients, medical personnel, and you.

Based on the data verified by the real world reference in 2021 and proven by the SCI paper, I was able to have hope as a demo of many hospitals, and I will make it an essential equipment in connection clinical practice through purchase.

It's not easy to get used to existing equipment, close your eyes and change the paradigm you used as a habit. It is a task that requires time to learn, learn, use, and make a habit of new things by taking a separate time without paying for the limited visits and hesitating to face-to-face due to COVID-19.

In clinical practice, the need for performance and effect is great, so that the effect of increasing use can be shared and actively changed through the society.

Before COVID-19, it was an opportunity to meet users in person through hospital seminar, medical device exhibitions, and academic exhibitions, introduce more detailed product information and efficient use of existing hospitals.

Despite difficult conditions, clinicians are expressing active interest in the real world reference due to its good performance and treatment effect, and the first goal in 2022 is to establish itself as an essential device in the first stage of domestic NICU, second stage of ICU, and third stage of global NICU.

It is a strategy to establish the foundation for IPO by establishing the first stage, and maximize the successful creation of value in the second stage, IPO in the second stage, and third stage.

It is to expand the brand and base with Anyfusion pump, and at the same time, develop and general-purpose HIS linked ACPI automation according to user needs.

We will make the dream of overcoming the medical community to contribute to patient healing with precision medical care so that we can have national pride and pride in pure Korea's original technology.

Anyfusion, our pure source technology, will be necessary for ICU and NICU patients to recover health, grow and develop normally, and lead the global market after decades of global top in cultures such as parasites, BTS, and squid games to become Korea's representative technology.

At the same time, ACPi, an anticancer drug preparation equipment, is general-purpose equipment.

As a result of manual ACPi demo, we are requesting an automatic ACPi equipped with HIS-linked BSC facilities like a robot that requires a lot of work. We are speeding up the development of automatic ACPI as we have identified the possibility of generalization at a cost-effectiveness that only ACPI can afford.

We would like to actively negotiate with global companies for globalization.

Our goal is to list and sell 10 demo hospitals, including Major Hospital, and we would like to achieve sales and net profit of more than 10 billion won by expanding the scope of use.

Thank you.